Incipiam Pharma ApS
Private limited companyCVR 44074214ValbyActive
Incipiam Pharma ApS is a private limited company, based in Valby, active in research and experimental development on natural sciences and engineering, founded in 2023. Equity was negative at the end of 2025 (−DKK 1.9m). The company made a loss in both 2024 and 2025, most recently DKK 1.8m. 4 other companies in the database are registered at the same address.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- The loss grew: from DKK 128k to DKK 1.8m (2024 → 2025).
Registrations, last 24 months
- 22/02/2026: Moved to Ottiliavej 9, 2500 Valby
- 12/03/2025: Moved to Ole Maaløes Vej 3, 2200 København N
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2023–2025 · amounts in DKK thousandEquity and net profit
| 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | – |
| Gross profit | −13 | −98 | −1,201 | −1,128.8% |
| Operating profit (EBIT) | −13 | −128 | −1,954 | −1,426.2% |
| Profit before tax | −13 | −128 | −2,402 | −1,776% |
| Net profit | −13 | −128 | −1,847 | −1,342.9% |
| Total assets | 27 | 4,472 | 8,795 | +96.7% |
| Equity | 27 | −101 | −1,949 | −1,820.1% |
| Liabilities | – | 4,574 | 10,744 | +134.9% |
| Cash and cash equivalents | – | 4,449 | 8,163 | +83.5% |
| Average number of employees | – | – | 1 | – |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresNegative equity
Equity was −DKK 1.9m at the end of 2025.
How is this calculated?
Equity in the latest annual report is below zero.
Loss for 3 years in a row
Net result has been negative in 2023–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
3 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/10/2024 – 30/09/2025 | 30/03/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 30/09/2024 | 31/01/2025 | The company | PDF not statedXBRL |
| 2023 | 23/05/2023 – 31/12/2023 | 14/06/2024 | The company | PDF not statedXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 68,883of 69,742 Better than 1% | No. 68,204of 69,964 Better than 3% |
| Same industry and fewer than 20 employees329 companies in the comparison | No. 252of 323 Better than 22% | No. 268of 329 Better than 19% |
| Companies that are founded within the last five years16,662 companies in the comparison | No. 16,331of 16,614 Better than 2% | No. 16,206of 16,661 Better than 3% |
| All companies of type ApS66,508 companies in the comparison | No. 65,706of 66,379 Better than 1% | No. 64,739of 66,505 Better than 3% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineering- Incipiam Pharma ApS−DKK 1.2m
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Incipiam Pharma ApS−DKK 1.8m
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
- Incipiam Pharma ApS−DKK 1.9m
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
- Incipiam Pharma ApS2
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- Mtc 2008 Holding ApS20%
- CTH Holding Invest ApS20%
- Bondo Hansen Holding ApS20%
- Gerhart-Hines Holding ApS20%
- Receptor Holding ApS10%
Management
1 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Casper Tind Hansen | CEO | 23/05/2023 |
- Founders
- CTH Holding Invest ApS
Signing rule: Selskabet tegnes af en direktør alene eller af den samlede Direktion i forening.
Address and production units
1 active production unitsOttiliavej 9
2500 Valby
København Municipality · Postcode 2500
Other companies at the address (4)
- H. Lundbeck A/SManufacture of pharmaceutical preparations
- Lundbeck Pharma A/SWholesale of pharmaceutical goods and nursing supplies
- Embark Laboratories ApSResearch and experimental development on natural sciences and engineering
- Embark Holdings ApSNon-financial holding companies
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Incipiam Pharma ApS | Ottiliavej 9, 2500 Valby | 2 | 1029337620 |
Purpose
Selskabets formål er at udføre aktiviteter relaterede til forskning og udvikling rettet mod fremstilling og kommercialisering af lægemidler inden for cardio-metabolske sygdomme og andre sygdomstilstande, og andre med lægemiddel-udvikling relaterede aktiviteter, samt at yde konsulentydelser til selskaber, som er beskæftigede indenfor selskabets hovedformål.
The purpose is quoted from the register in Danish.
Changes year by year
13 registered events20262 changesaccounts 1 · address 1
- AccountsAnnual report for 2025 published
- AddressMoved to Ottiliavej 9, 2500 Valby
20253 changesaddress 1 · accounts 1 · industry 1
- AddressMoved to Ole Maaløes Vej 3, 2200 København N
- AccountsAnnual report for 2024 published
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
20241 changeaccounts 1
- AccountsAnnual report for 2023 published
20237 changesfounded 1 · management 1 · ownership 5
- FoundedRegistered as Incipiam Pharma ApS
- ManagementCasper Tind Hansen appointed ceo
- OwnershipMTC 2008 HOLDING ApS registered as owner (20%)
- OwnershipCTH Holding Invest ApS registered as owner (20%)
- OwnershipBondo Hansen Holding ApS registered as owner (20%)
- OwnershipGerhart-Hines Holding ApS registered as owner (20%)
- OwnershipReceptor Holding ApS registered as owner (10%)
Related companies
Same industry in København
- Genmab A/S676 employees
- 3shape A/S518 employees
- Carlsberg A/S107 employees
- IQVIA RDS Denmark A/S100 employees
- Nuevolution A/S100 employees
- Sunshine Enterprise Holding A/S73 employees
Same people in management
- Blue Cell Therapeutics ApSvia Casper Tind Hansen
- Ceremedy ApSvia Casper Tind Hansen
- Embark Laboratories ApSvia Casper Tind Hansen
- Embark Holdings ApSvia Casper Tind Hansen
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.